Branded Generics Market Report 2026

The branded generics market size has grown rapidly in recent years. It will grow from $393.5 billion in 2025 to $434.56 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to patent expirations of key drugs, growing generic drug acceptance, rising healthcare expenditure, government support for generics, increasing prevalence of chronic diseases.

The branded generics market size is expected to see rapid growth in the next few years. It will grow to $653.17 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to expansion of branded generics portfolio, adoption of digital marketing in pharma, increasing partnerships with healthcare providers, growth in emerging markets, advancements in drug formulation technologies. Major trends in the forecast period include increasing brand awareness among patients, marketing strategies focused on differentiation, growth in prescription volume for branded generics, rising physician preference for branded generics, expansion of emerging markets for generic drugs.

The rising prevalence of chronic diseases is expected to drive growth in the branded generics market. Chronic diseases are long-lasting conditions that often cannot be fully cured, but can be managed and controlled. Their incidence is increasing due to factors such as tobacco use, poor nutrition, physical inactivity, and excessive alcohol consumption. Globally, consumers are increasingly opting for branded generics to manage chronic diseases, as these medications are more affordable than standard treatments. For example, in April 2025, the Centers for Disease Control and Prevention, a US-based federal agency, reported that in 2023, approximately 76.4% of U.S. adults had at least one of 12 selected chronic conditions, and 51.4% had multiple chronic conditions. Therefore, the growing prevalence of chronic diseases is boosting demand for branded generics.

Leading companies in the branded generics market are forming partnerships to leverage each other’s resources and expand into new regions. In September 2024, Biocon Ltd., an India-based pharmaceutical company, partnered with Tabuk Pharmaceuticals. Biocon is responsible for the development and manufacturing of GLP-1 products, ensuring high-quality biopharmaceuticals for diabetes treatment, while Tabuk Pharmaceuticals manages marketing authorization, registration, importation, and promotion of these products across the Middle East, particularly Saudi Arabia. The agreement also allows future expansion into additional GLP products, providing a wider range of diabetes treatments. The partnership aims to deliver innovative healthcare solutions that improve patient well-being in Saudi Arabia and surrounding regions, reflecting both companies’ commitment to enhancing healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based company that markets branded and generic pharmaceutical products.

In May 2023, Yaral Pharma, a Switzerland-based pharmaceutical company, collaborated with Eversana Life Science Services LLC to expand its pain and endocrinology product portfolio in the U.S. By partnering with Eversana, Yaral Pharma gains comprehensive commercialization support, including logistics and operational services. Eversana Life Science Services LLC is a U.S.-based company providing end-to-end commercialization and consulting services for the life sciences sector.

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the branded generics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and packaging materials, creating challenges in production cost management. Markets such as North America and Europe, which rely heavily on imported APIs, are most affected, while segments like oral and parenteral drugs face higher supply chain disruptions. However, tariffs have encouraged local manufacturing investments and diversification of sourcing strategies, potentially improving domestic production capabilities and long-term supply security.

The branded generics market research report is one of a series of new reports that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Branded generics are unregistered drugs marketed under a brand name, offering benefits that encourage patients and healthcare providers to choose them over other options. These are generic medications that carry a distinctive brand name and may be promoted in ways similar to branded drugs.

The main classes of branded generics include alkylating agents, antimetabolites, hormones, anti-hypertensives, lipid-lowering drugs, antidepressants, antipsychotics, antiepileptics, and other medications. Alkylating agents, a subclass of anticancer or antineoplastic drugs, work by preventing the conversion of DNA into RNA, thereby halting protein synthesis. These agents add alkyl groups to hydrogen atoms on DNA, creating cross-links within the DNA chain and producing cytotoxic, mutagenic, and carcinogenic effects. Branded generics are administered via various routes, including topical, oral, parenteral, and others. They are used to treat multiple medical conditions, including oncology, cardiovascular diseases, diabetes, neurological disorders, gastrointestinal diseases, dermatological conditions, as well as for analgesic and anti-inflammatory purposes, among others.

The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.